Literature DB >> 2067849

Localization of regulatory elements controlling human MYCN expression.

S Hiller1, S Breit, Z Q Wang, E F Wagner, M Schwab.   

Abstract

Expression of the cellular oncogene MYCN is restricted to few cell lineages and is highest during development both in mouse and in humans. In pursuit of elucidating the mechanisms underlying MYCN regulation we introduced a human MYCN clone (pNb-9) with approximately 2.5 kbp 5'- and 6 kbp 3'-flanking genomic sequences into different murine and human cell lines as well as into mice. In all cases we found a correlation between the expression of the exogenous and the endogenous MYCN. Among cell lines, only those expressing the endogenous gene also expressed the transfected gene. In the transgenic mice transcripts of the transgene were present in proportion to the transcripts of the endogenous MYCN gene with the highest level in the brain. Therefore, the genetic information necessary for regulated expression of MYCN appears to be contained in pNb-9. To localize the DNA-regions responsible for regulated expression, we generated MYCN/CAT hybrid genes with different portions of the putative MYCN promoter region linked to the reporter gene. Transient transfections into various murine and human cell lines identified three DNA regions apparently involved in the regulation of expression. One region about 200 bp upstream of the transcriptional start site is responsible for a basal level of MYCN expression. A second region located about 800 bp further upstream appears to be involved in cell type-specific gene activation. The third regulatory element is located at the 3' end of the first exon and/or in the first intron and may mediate tissue-specific down regulation of gene expression.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2067849

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  8 in total

1.  Expression of the woodchuck N-myc2 retroposon in brain and in liver tumors is driven by a cryptic N-myc promoter.

Authors:  G Fourel; C Transy; B C Tennant; M A Buendia
Journal:  Mol Cell Biol       Date:  1992-12       Impact factor: 4.272

2.  Cooperative action of multiple cis-acting elements is required for N-myc expression in branchial arches: specific contribution of GATA3.

Authors:  Eric Potvin; Laurent Beuret; Jean-François Cadrin-Girard; Marcelle Carter; Sophie Roy; Michel Tremblay; Jean Charron
Journal:  Mol Cell Biol       Date:  2010-09-20       Impact factor: 4.272

3.  Differential regulation of the N-myc proto-oncogene by ROR alpha and RVR, two orphan members of the superfamily of nuclear hormone receptors.

Authors:  I Dussault; V Giguère
Journal:  Mol Cell Biol       Date:  1997-04       Impact factor: 4.272

4.  Dissection of the MYCN locus in Feingold syndrome and isolated oesophageal atresia.

Authors:  Marie Cognet; Agnés Nougayrede; Valérie Malan; Patrick Callier; Celia Cretolle; Laurence Faivre; David Genevieve; Alice Goldenberg; Delphine Heron; Sandra Mercier; Nicole Philip; Sabine Sigaudy; Alain Verloes; Sabine Sarnacki; Arnold Munnich; Michel Vekemans; Stanislas Lyonnet; Heather Etchevers; Jeanne Amiel; Loïc de Pontual
Journal:  Eur J Hum Genet       Date:  2011-01-12       Impact factor: 4.246

5.  Identification of BSAP (Pax-5) target genes in early B-cell development by loss- and gain-of-function experiments.

Authors:  S L Nutt; A M Morrison; P Dörfler; A Rolink; M Busslinger
Journal:  EMBO J       Date:  1998-04-15       Impact factor: 11.598

6.  MYCN Amplification in Neuroblastoma: a Paradigm for the Clinical Use of an Oncogene.

Authors:  Manfred Schwab
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

7.  A novel intron element operates posttranscriptionally To regulate human N-myc expression.

Authors:  L E Sivak; G Pont-Kingdon; K Le; G Mayr; K F Tai; B T Stevens; W L Carroll
Journal:  Mol Cell Biol       Date:  1999-01       Impact factor: 4.272

8.  MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines.

Authors:  Nevim Aygun; Oguz Altungoz
Journal:  Mol Med Rep       Date:  2018-11-22       Impact factor: 2.952

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.